AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use
Completed
- Conditions
- GERD
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5234
- Registration Number
- NCT00691171
Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2008-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT00691353
- Locations
- 🇬🇷
Research Site, Thiva, Greece
Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00690612
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Moderate to Severe COPD
- Interventions
- Drug: PlaceboDrug: AZD1981
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2014-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 118
- Registration Number
- NCT00690482
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00690404
Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00689780
- Locations
- 🇸🇪
Research Site, Upssala, Sweden
Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386
Phase 1
Completed
- Conditions
- Chronic Pain
- Interventions
- Drug: AZD1386Drug: Placebo
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 69
- Registration Number
- NCT00690079
- Locations
- 🇬🇧
Research Site, Macclesfield, Cheshire, United Kingdom
Safety and Efficacy of Switching to Quetiapine in Outpatients With Schizophrenia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 576
- Registration Number
- NCT00690365
Depressive Symptoms in Acute Manic Episode
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00690248
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: AZD6370Drug: Placebo
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00690287
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath